Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.600
+0.060 (1.32%)
Aug 6, 2026, 10:30 AM EDT - Market open

Prelude Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-12.147---
Revenue Growth
-73.43%----
Gross Profit
-12.147---
Selling, General & Admin
21.7722.4128.7228.8830.6526.96
Research & Development
79.0994.3118103.3992.8986.78
Total Operating Expenses
100.86116.71146.71132.28123.54113.74
Operating Income
-84.14-104.57-139.71-132.28-123.54-113.74
Total Non-Operating Income (Expense)
6.345.0712.5410.458.12.04
Pretax Income
-77.8-99.5-127.17-121.83-115.44-111.69
Net Income
-77.8-99.5-127.17-121.83-115.44-111.69
Net Income to Common
-77.8-99.5-127.17-121.83-115.44-111.69
Net Income Growth
------
Shares Outstanding (Basic)
797776604746
Shares Outstanding (Diluted)
797776604746
Shares Change
3.59%1.52%25.60%27.41%2.87%269.03%
EPS (Basic)
-1.00-1.29-1.68-2.02-2.44-2.43
EPS (Diluted)
-1.00-1.29-1.68-2.02-2.44-2.43
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-43.78-56.37-103.65-110.58-86.75-85.85
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.56-0.73-1.37-1.83-1.83-1.86
Gross Margin
-100.00%100.00%---
Operating Margin
--861.33%-1995.91%---
Profit Margin
--819.59%-1816.76%---
FCF Margin
--464.32%-1480.74%---
EBITDA
-82.47-102.86-137.94-131.11-122.22-112.82
EBITDA Margin
--847.24%-1970.60%---
EBIT
-84.14-104.57-139.71-132.28-123.54-113.74
EBIT Margin
--861.33%-1995.91%---
SEC Filings: 10-K · 10-Q